Alzamend Neuro Inc (ALZN) Share Price

Pure 100% bull shit
Ault cost my family $250,000 with his band of merry men

ALZN 1.02 52 week low 2 out of 3 good flips premarket..stopped out at 1.09 on trade 3 .. Major dilution obviously 12m traded. Find a tradeable bottom for round 3 but would wait until
Afternoon. Other plays going well CSAI $12.33 and IBIO longer term

Round 3 in with 1.12 stop loss 1.09 diluting pig for sure just playing the zones a dangerous play for sure 

ALZN $1.22 Round 3 only if can get some under $1.15 if not good luck as 1.50s most probable resistance zone on regular trading hours 

this isn't the automaker, but still a cool device

ALZN $1.31 + 20% probably headed back to 1.50s resistance zone but taking safe profit.
AI and Tesla used in brain definitely good news ..

$1.24 flip back out 80% .. “We want to thank Tesla for working with us to create this one-of-a-kind lithium head coil,” stated Stephan Jackman, Chief Executive Officer of Alzamend. “The development of the coil was a long time coming, but we believe the time and effort was necessary to allow us unprecedented knowledge as to how lithium interacts within our brains. We believe that our upcoming studies, utilizing the head coil, has the potential to broaden the application of lithium treatment across numerous neurodegenerative diseases and psychiatric disorders. Its completion allows us to solidify our timeline for the forthcoming clinical trials in collaboration with Massachusetts General Hospital. We look forward to sharing additional details regarding these trials soon.”...

Back in 1.18 for round 2 stop loss 1.15 they almost diluted 9m shares now. See
What happens round 1 was the money maker 

alzn.............................................https://stockcharts.com/h-sc/ui?s=alzn&p=W&b=5&g=0&id=p86431144783

$1.90s nice Tesla news on top of bottom play..
...(“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced the completion of a groundbreaking head coil by Tesla Dynamic Coils BV (“Tesla”). The development of the head coil was necessary to facilitate the five upcoming Phase II clinical trials to be conducted by Alzamend....This

$1.83 + 70% out of remaining 20% 

$1.46 +'35% now we talking quick flipper out of 80%

$1.05 new bottom
Been holding..Alzheimer's low floater but does have a backer 

This year, Alzamend entered into a securities purchase agreement with an institutional investor to purchase up to $25 million of preferred stock and warrants over a two-year period. In addition, Alzamend entered into an at-the-market sales agreement, with the right of Alzamend to strategically sell up to $6.5 million of common stock at its option. Please see Alzamend’s Commission filings for additional information regarding these agreements and the terms of such financing transactions.
 
“These financing transactions have allowed us to greatly improve our financial situation” said Stephan Jackman, Chief Executive Officer of Alzamend. “In the first six months of this fiscal year, we have gone from a stockholder deficit to several million in stockholder equity, significantly reduced our outstanding liabilities and increased our cash on hand. These financial improvements allowed us to regain compliance with all applicable requirements for our stock to continue to be listed on Nasdaq and provides us with the capital in preparation of the upcoming clinical trials to be initiated in 2025.”

ALZN The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern. As of October 31, 2024, the Company had cash of $4.1 million, working capital of $3.5 million, an accumulated deficit of $56.4 million and stockholders’ equity of $3.8 million. For the three and six months ended October 31, 2024, the Company had net losses of $1.4 million and $2.4 million, respectively. For the six months ended October 31, 2024, cash used in operating activities was $4.5 million. Historically, the Company has financed its operations principally through issuances of equity and debt instruments.
 

 
We intend to develop and commercialize therapeutics and vaccines that are better than existing treatments and have the potential to significantly improve the lives of individuals afflicted by Alzheimer’s, BD, MDD and PTSD. To achieve these goals, we are pursuing the following key business strategies:
 
· Advance clinical development of AL001 for Alzheimer’s, BD, MDD and PTSD treatment;
 
· Advance clinical development of ALZN002 for Alzheimer’s treatment;
 
· Expand our pipeline of pharmaceuticals to include additional indications for AL001 and delivery methods;
 
· Focus on translational and functional endpoints to efficiently develop product candidates; and
 
· Optimize the value of AL001 and ALZN002 in major markets.
 
Our pipeline consists of two novel therapeutic drug candidates:
 
· AL001 - A patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the “Licensor”); and
 
· ALZN002 - A patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s throu

Our most advanced product candidate (lead product) licensed and in clinical development in humans is AL001, an ionic cocrystal of lithium for the treatment of Alzheimer’s, BD, MDD and PTSD. Based on our preclinical data involving mice models, AL001 treatment prevented cognitive deficits, depression and irritability and is superior in improving associative learning and memory and irritability compared with lithium carbonate treatments, supporting the potential of this lithium formulation for the treatment of Alzheimer’s, BD, MDD and PTSD in humans. Lithium has been marketed for more than 35 years and human toxicology regarding lithium use has been well characterized, potentially mitigating the regulatory burden for safety data.
 

At-the-Market Offering
 
On October 3, 2024, we entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC (the “ATM Offering”), as sales agent to sell shares of our common stock, having an aggregate offering price of up to approximately $6.5 million from time to time, through the ATM Offering. On October 3, 2024, we filed a prospectus supplement with the SEC relating to the offer and sale of up to approximately $6.5 million in shares of common stock in the ATM Offering.
 
The offer and sale of the shares will be made pursuant to our effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-273610) filed with the SEC on August 2, 2023 and declared effective by the SEC on August 10, 2023.
 
During the six months ended October 31, 2024, we sold an aggregate of 755,888 shares of common stock pursuant to the ATM Offering for gross and net proceeds of $1.2 million. From November 1, 2024 to December 10, 2024, we sold an aggregate of 201,543 shares of common stock pursuant to the ATM Offering for gross and net proceeds of $280,000.



This year, Alzamend entered into a securities purchase agreement with an institutional investor to purchase up to $25 million of preferred stock and warrants over a two-year period. In addition, Alzamend entered into an at-the-market sales agreement, with the right of Alzamend to strategically sell up to $6.5 million of common stock at its option. Please see Alzamend’s Commission filings for additional information regarding these agreements and the terms of such financing transactions. “These financing transactions have allowed us to greatly improve our financial situation” said Stephan Jackman, Chief Executive Officer of Alzamend. “In the first six months of this fiscal year, we have gone from a stockholder deficit to several million in stockholder equity, significantly reduced our outstanding liabilities and increased our cash on hand. These financial improvements allowed us to regain compliance with all applicable requirements for our stock to continue to be listed on Nasdaq and provides us with the capital in preparation of the upcoming clinical trials to be initiated in 2025.”
ALZN The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern. As of October 31, 2024, the Company had cash of $4.1 million, working capital of $3.5 million, an accumulated deficit of $56.4 million and stockholders’ equity of $3.8 million. For the three and six months ended October 31, 2024, the Company had net losses of $1.4 million and $2.4 million, respectively. For the six months ended October 31, 2024, cash used in operating activities was $4.5 million. Historically, the Company has financed its operations principally through issuances of equity and debt instruments. 
 We intend to develop and commercialize therapeutics and vaccines that are better than existing treatments and have the potential to significantly improve the lives of individuals afflicted by Alzheimer’s, BD, MDD and PTSD. To achieve these goals, we are pursuing the following key business strategies: · Advance clinical development of AL001 for Alzheimer’s, BD, MDD and PTSD treatment; · Advance clinical development of ALZN002 for Alzheimer’s treatment; · Expand our pipeline of pharmaceuticals to include additional indications for AL001 and delivery methods; · Focus on translational and functional endpoints to efficiently develop product candidates; and · Optimize the value of AL001 and ALZN002 in major markets. Our pipeline consists of two novel therapeutic drug candidates: · AL001 - A patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the “Licensor”); and · ALZN002 - A patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s throu
Our most advanced product candidate (lead product) licensed and in clinical development in humans is AL001, an ionic cocrystal of lithium for the treatment of Alzheimer’s, BD, MDD and PTSD. Based on our preclinical data involving mice models, AL001 treatment prevented cognitive deficits, depression and irritability and is superior in improving associative learning and memory and irritability compared with lithium carbonate treatments, supporting the potential of this lithium formulation for the treatment of Alzheimer’s, BD, MDD and PTSD in humans. Lithium has been marketed for more than 35 years and human toxicology regarding lithium use has been well characterized, potentially mitigating the regulatory burden for safety data. 
At-the-Market Offering On October 3, 2024, we entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC (the “ATM Offering”), as sales agent to sell shares of our common stock, having an aggregate offering price of up to approximately $6.5 million from time to time, through the ATM Offering. On October 3, 2024, we filed a prospectus supplement with the SEC relating to the offer and sale of up to approximately $6.5 million in shares of common stock in the ATM Offering. The offer and sale of the shares will be made pursuant to our effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-273610) filed with the SEC on August 2, 2023 and declared effective by the SEC on August 10, 2023. During the six months ended October 31, 2024, we sold an aggregate of 755,888 shares of common stock pursuant to the ATM Offering for gross and net proceeds of $1.2 million. From November 1, 2024 to December 10, 2024, we sold an aggregate of 201,543 shares of common stock pursuant to the ATM Offering for gross and net proceeds of $280,000.

Headed sub $1

Sucker
Ault the thief

Add 1.10s on this micro float 

Added some $1.20s chart wise makes
Sense lower descending W on chart making form . Tiny floater 

Baloney via the Ault baloney mill
Cost us 1/4 of a mill

GM 20122

“This is a major step towards potentially providing an important treatment innovation for the 43+ million Americans afflicted with Alzheimer’s, BD, MDD and PTSD. These results demonstrated the potential of AL001 to enhance brain-specific lithium delivery while minimizing systemic exposure in an Alzheimer’s disease mouse model, guiding development of enhanced lithium effectiveness and safety in human diseases,” said Stephan Jackman, Chief Executive Officer of Alzamend. “

Mice lithium dementia Alzheimer's bipolar. Gets a little bump here. In some $1.39 low floater 2m

Junk

Dust in the wind

Don’t blink

Headed sub $1.25 on the way to .99 then……

ALZN under $2

Every day
Ault sells snake oil

ALZN new 52 week low

ALZN new 52=week low

ALZN new 52+week low

Now!!!

Headed sub $2 then submerged in the Aulty swamp

ALZN under $3

Doomed-dead-over
SUCKERS don’t be!!

$3…..$3
Hahahaha

down .60!!

Timber suckers

WAS ALREADY TO $5 IN JUST FEW HOURS AFTER TOUCHING THE $15

3 to 15 back to 4 in one day🥴

bought as low as 4.77 in the aftermarket. Will start selling somewhere in the $6 range if its hit, nothings guaranteed

Ah see the Ault kiss of death?

well, finally finally we got some serious movement. Glad I bought all the way down to 2 bucks, it was painful, but I got used to the pain. I sold out 3/4 of my total position at various prices up to the top and started trading back in for a trading position. Raise a huge amount of cash. A number of these stocks go thru this craziness (BTTR, SXTP) where its algos doing all or most of the trading. At $8 I would be a buyer under that, and a seller over 10 bucks. What it does nobody I repeat nobody knows, you dont have to know, you just need to be alert, take profits, and buy back in at reasonable prices. Dont make it more complicated than that. I probably should have sold my entire position but heck, it just kept going, crazy really.

Won’t

Pump/dump in effect

History dictates Ault stock dies

$ALZN +638% @ HOD 15.06...in play for dip & bounce...

WTF? Same news? On closer look...

Pretty clever, seems to have worked. Rack 'em, lol...

$ALZN

ALZN..................................https://stockcharts.com/h-sc/ui?s=ALZN&p=W&b=5&g=0&id=p86431144783

ALZN: INDEED!!! (Just wait until the proverbial SHIT-HITS-THE-FAN behind this SCAMMING-PR's company!!!)

MAKE THAT MONEY!!!

ALZN: IDENTICAL "news" --- biggest SCAM PR of the year!!! (Will be on "60-Minutes" shortly.)

MAKE THAT MONEY!!!